Systems for the controlled release of macromolecules
First Claim
Patent Images
1. A therapeutic system for the continuous and controlled administration of insulin, said system being in the form of a body which is sized and shaped for placement in the environment of use, comprising a two-phase composition of:
- (a) a first phase comprising a biocompatible, plastically deformable, hydrophobic matrix having an aqueous fluid sorptivity not greater than 50% by weight, of ethylene-vinyl ester copolymer of the general formula;
##STR2## wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 7 carbons and phenyl, the polymer being insoluble in the environment of use, substantially impermeable to diffusion therethrough of insulin, and containing in admixture therewith;
(b) a second phase comprising from about 3 to 90 parts by weight of agglomerated particles of insulin.
2 Assignments
0 Petitions
Accused Products
Abstract
Delivery systems manufactured in the form of polymeric compositions for the controlled delivery of macromolecules to environments of use are disclosed. The systems are characterized as two-phase compositions comprising a phase formed of an insoluble polymeric matrix having limited water sorptivity containing in admixture therein an interpenetrating phase formed of a particulate hydrophilic water swellable, biologically active macromolecular material.
163 Citations
12 Claims
-
1. A therapeutic system for the continuous and controlled administration of insulin, said system being in the form of a body which is sized and shaped for placement in the environment of use, comprising a two-phase composition of:
-
(a) a first phase comprising a biocompatible, plastically deformable, hydrophobic matrix having an aqueous fluid sorptivity not greater than 50% by weight, of ethylene-vinyl ester copolymer of the general formula;
##STR2## wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 7 carbons and phenyl, the polymer being insoluble in the environment of use, substantially impermeable to diffusion therethrough of insulin, and containing in admixture therewith;(b) a second phase comprising from about 3 to 90 parts by weight of agglomerated particles of insulin. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
Specification